Sitagliptin Compared with Thiazolidinediones as a Third-Line Oral Antihyperglycemic Agent in Type 2 Diabetes Mellitus
Authors:
- Stanley H. HsiaSHStanley H. Hsia
- Maria D. NavarMNMaria D. Navar
- Petra DuranPDPetra Duran
- Magda ShaheenMSMagda Shaheen
- Mayer B. DavidsonMDMayer B. Davidson
- 1 September 2011
- journal article
- clinical trial
- Published by Elsevier in Endocrine Practice
- Vol. 17 (5) , 691-698
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetesBMC Endocrine Disorders, 2010
- Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2010
- SitagliptinDrugs, 2010
- Thiazolidinediones and Congestive Heart FailureCardiology in Review, 2009
- Bone metabolism in type 2 diabetes and role of thiazolidinedionesCurrent Opinion in Endocrinology, Diabetes and Obesity, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- The Role of Incretins in Glucose Homeostasis and Diabetes TreatmentPharmacological Reviews, 2008
- Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*Diabetes, Obesity and Metabolism, 2008
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetesCurrent Medical Research and Opinion, 2008
- Comparison of the Glycemic Effects of Rosiglitazone and Pioglitazone in Triple Oral Therapy in Type 2 DiabetesDiabetes Care, 2006